Corticosteroid-free Kidney Transplantation Improves Growth
Authors:
- Nicholas J. A. WebbNWNicholas J. A. Webb
- Sarah E. DouglasSDSarah E. Douglas
- Azita RajaiARAzita Rajai
- Stephen A. RobertsSRStephen A. Roberts
- Ryszard GrendaRyszard Grenda
- Stephen D. MarksSMStephen D. Marks
- Alan R. WatsonAWAlan R. Watson
- Maggie FitzpatrickMFMaggie Fitzpatrick
- Karel VondrakKVKarel Vondrak
- Heather MaxwellHMHeather Maxwell
- Jeno JarayJJJeno Jaray
- Rita Van Damme-LombaertsRDRita Van Damme-Lombaerts
- 1 June 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 99 (6) , 1178-1185
Abstract
Corticosteroid withdrawal (CW) after pediatric kidney transplantation potentially improves growth while avoiding metabolic and other adverse events. We have recently reported the results of a 196 subject randomized controlled trial comparing early CW (tacrolimus, mycophenolate mofetil (MMF), daclizumab, and corticosteroids until day 4) with tacrolimus, MMF, and corticosteroid continuation (CC). At 6 months, CW subjects showed better growth with no adverse impact on acute rejection or graft survival (Am J Transplant 2010; 10: 828-836). This 2-year investigator-driven follow-up study aimed to determine whether improved growth persisted in the longer term. Data regarding growth, graft outcomes and adverse events were collected at 1 year (113 patients) and 2 years (106 patients) after transplantation. The primary endpoint, longitudinal growth calculated as delta height standard deviation score, was analyzed using a mixed model repeated measures model. Corticosteroid withdrawal subjects grew better at 1 year (difference in adjusted mean change, 0.25; 95% confidence interval, 0.10, 0.40; P = 0.001). At 2 years, growth remained numerically better in CW subjects (0.20 (-0.01, 0.41); P = 0.06), and significantly better in prepubertal subjects (0.50 (0.16, 0.84); P = 0.004). Bacterial and viral infection was significantly more common in CW subjects at 1 year only. Corticosteroid withdrawal and CC subjects received similar exposure to both tacrolimus and MMF at 1 and 2 years. No significant difference in patient or graft survival, rejection, estimated glomerular filtration rate, or other adverse events was detected. Early CW effectively and safely improves growth up to 2 years after transplantation, particularly in prepubertal children.Keywords
This publication has 24 references indexed in Scilit:
- Complete Steroid Avoidance Is Effective and Safe in Children With Renal Transplants: A Multicenter Randomized Trial With Three-Year Follow-UpAmerican Journal of Transplantation, 2012
- Pediatric Kidney Transplantation Followed by De Novo Therapy With Everolimus, Low-Dose Cyclosporine A, and Steroid Elimination: 3-Year DataTransplantation, 2011
- Growth after renal transplantationPediatric Nephrology, 2009
- Growth and weight gain of prepubertal children after cardiac transplantationPediatric Transplantation, 2007
- Results of one‐year follow‐up of steroid‐free immunosuppression in pediatric renal transplant patientsPediatric Transplantation, 2005
- Successful Withdrawal of Steroids in Pediatric Renal Transplant Recipients Receiving Cyclosporine A and Mycophenolate Mofetil Treatment: Results after Four YearsTransplantation, 2004
- Factors Affecting Catch-up Growth After Liver TransplantationJournal of Pediatric Endocrinology and Metabolism, 2004
- Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation1Transplantation, 2003
- PROMISING EARLY OUTCOMES WITH A NOVEL, COMPLETE STEROID AVOIDANCE IMMUNOSUPPRESSION PROTOCOL IN PEDIATRIC RENAL TRANSPLANTATION1Transplantation, 2001
- Pediatric renal transplantation without steroidsPediatric Nephrology, 1998